EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

Spinal Muscular Atrophy Treatment in Patients Identified by Newborn Screening—A Systematic Review

Karolina Aragon-Gawinska, Charlotte Mouraux iD, Tamara Dangouloff, Laurent Servais iD

Genes · 29.06.2023 · 14 (7) · 1377

DOI: 10.3390/genes14071377 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Genes, online erschienen am 29.06.2023. Verfasst von Karolina Aragon-Gawinska und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Medical University of Warsaw, 02-097 Warsaw, Poland. Hauptthemen laut MEDLINE: Neonatal Screening, Muscular Atrophy, Spinal. Die Arbeit wurde bisher 101-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In spinal muscular atrophy, clinical trial results indicated that disease-modifying treatments are highly effective when given prior to symptom onset, which has prompted newborn screening programs in growing number of countries. However, prognosis of those patients cannot be inferred from clinical trials conducted in presymptomatic individuals, as in some cases disease presents very early. Methods: we conducted a systematic review of articles published up to January 2023.

Results

Among 35 patients with three SMN2 copies treated before 42 days of age and followed-up for at least 18 months, all but one achieved autonomous ambulation. Of 41 patients with two SMN2 copies, who were non-symptomatic at treatment initiation, all achieved a sitting position independently and 31 were able to walk. Of 16 patients with two SMN2 copies followed-up for at least 18 months who presented with symptoms at treatment onset, 3 achieved the walking milestone and all but one were able to sit without support. Conclusions: evaluation of data from 18 publications indicates that the results of early treatment depend on the number of SMN2 copies and the initial neurological status of the patient.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neonatal ScreeningMuscular Atrophy, SpinalInfant, NewbornHumansPrognosisTime

Stichwörter der Autor:innen

PCRgene therapynewborn screeningspinal muscular atrophy

Autor:innen und Institutionen

  • Department of Neurology, Medical University of Warsaw, 02-097 Warsaw, Poland.
  • Neuromuscular Reference Center, Department of Pediatrics, University Hospital Liège, University of Liège, 4000 Liège, Belgium.
  • MDUK Oxford Neuromuscular Centre & NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford OX3 0ER, UK.

ORCID-Profile: Charlotte Mouraux, Laurent Servais

Zitieren

APA

Aragon-Gawinska, K., Mouraux, C., Dangouloff, T., & Servais, L. (2023). Spinal Muscular Atrophy Treatment in Patients Identified by Newborn Screening—A Systematic Review. Genes, 14(7), 1377. https://doi.org/10.3390/genes14071377

Vancouver

Aragon-Gawinska K, Mouraux C, Dangouloff T, Servais L. Spinal Muscular Atrophy Treatment in Patients Identified by Newborn Screening—A Systematic Review. Genes. 2023;14(7):1377. doi:10.3390/genes14071377

BibTeX
@article{AragonGawinska2023,
  author = {Aragon-Gawinska, Karolina and Mouraux, Charlotte and Dangouloff, Tamara and Servais, Laurent},
  title = {Spinal Muscular Atrophy Treatment in Patients Identified by Newborn Screening—A Systematic Review},
  journal = {Genes},
  year = {2023},
  volume = {14},
  number = {7},
  pages = {1377},
  doi = {10.3390/genes14071377}
}
Kostenlos starten →